IMMUNOVANT, INC. Stock-Based Compensation
IMMUNOVANT, INC. (IMVT) reported Stock-Based Compensation of $13.77 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- IMMUNOVANT, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $13.77M, a 25.59% decline year-over-year.
- IMMUNOVANT, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $11.14M, a 4.67% decline year-over-year.
- IMMUNOVANT, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $12.71M, a 9.12% increase year-over-year.
- IMMUNOVANT, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $13.36M, a 5.24% increase year-over-year.
- IMMUNOVANT, INC. share-based payment arrangement, noncash expense for fiscal 2026 was $55.72M, a 12.60% increase from fiscal 2025.
- IMMUNOVANT, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $49.49M, a 20.36% increase from fiscal 2024.
- IMMUNOVANT, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $41.12M, a 27.31% increase from fiscal 2023.
- IMMUNOVANT, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $32.30M, a 5.69% decline from fiscal 2022.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.77M 10-Q · filed 2026-08-06 | $24.91M derived: sum of 2 quarters · filed 2026-08-06 | $37.63M derived: sum of 3 quarters · filed 2026-08-06 | $50.99M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $11.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $23.86M derived: sum of 2 quarters · filed 2026-05-20 | $37.21M derived: sum of 3 quarters · filed 2026-05-20 | $55.72M 10-K · filed 2026-05-20 |
| 2025-12-31 | $12.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | $26.07M derived: sum of 2 quarters · filed 2026-02-06 | $44.58M 10-Q · filed 2026-02-06 | $56.27M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-09-30 | $13.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10 | $31.87M 10-Q · filed 2025-11-10 | $43.55M derived: sum of 3 quarters · filed 2026-08-06 | $55.21M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $18.51M 10-Q · filed 2026-08-06 | $30.20M derived: sum of 2 quarters · filed 2026-08-06 | $41.85M derived: sum of 3 quarters · filed 2026-08-06 | $54.54M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $11.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $23.34M derived: sum of 2 quarters · filed 2026-05-20 | $36.03M derived: sum of 3 quarters · filed 2026-05-20 | $49.49M 10-K · filed 2026-05-20 |
| 2024-12-31 | $11.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | $24.34M derived: sum of 2 quarters · filed 2026-02-06 | $37.80M 10-Q · filed 2026-02-06 | $47.48M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-09-30 | $12.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10 | $26.15M 10-Q · filed 2025-11-10 | $35.83M derived: sum of 3 quarters · filed 2026-05-20 | $46.05M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-06-30 | $13.46M 10-Q · filed 2025-08-11 | $23.13M derived: sum of 2 quarters · filed 2026-05-20 | $33.35M derived: sum of 3 quarters · filed 2026-05-20 | $43.88M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-03-31 | $9.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $19.90M derived: sum of 2 quarters · filed 2026-05-20 | $30.43M derived: sum of 3 quarters · filed 2026-05-20 | $41.12M 10-K · filed 2026-05-20 |
| 2023-12-31 | $10.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-06 | $20.75M derived: sum of 2 quarters · filed 2025-02-06 | $31.44M 10-Q · filed 2025-02-06 | $38.98M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-09-30 | $10.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-07 | $21.22M 10-Q · filed 2024-11-07 | $28.76M derived: sum of 3 quarters · filed 2025-05-29 | $37.67M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-06-30 | $10.69M 10-Q · filed 2024-08-06 | $18.23M derived: sum of 2 quarters · filed 2025-05-29 | $27.14M derived: sum of 3 quarters · filed 2025-05-29 | $35.30M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-03-31 | $7.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-29 | $16.45M derived: sum of 2 quarters · filed 2025-05-29 | $24.61M derived: sum of 3 quarters · filed 2025-05-29 | $32.30M 10-K · filed 2025-05-29 |
| 2022-12-31 | $8.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-12 | $17.06M derived: sum of 2 quarters · filed 2024-02-12 | $24.75M 10-Q · filed 2024-02-12 | $36.61M derived: sum of 4 quarters · filed 2024-02-12 |
| 2022-09-30 | $8.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-09 | $15.84M 10-Q · filed 2023-11-09 | $27.71M derived: sum of 3 quarters · filed 2023-11-09 | $37.87M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $7.69M 10-Q · filed 2023-08-10 | $19.55M derived: sum of 2 quarters · filed 2023-08-10 | $29.71M derived: sum of 3 quarters · filed 2023-08-10 | $38.07M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $11.86M derived: 10-K 12 month − 10-Q 9 month · filed 2023-05-22 | $22.02M derived: sum of 2 quarters · filed 2023-05-22 | $30.38M derived: sum of 3 quarters · filed 2023-05-22 | $34.24M 10-K · filed 2023-05-22 |
| 2021-12-31 | $10.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-03 | $18.52M derived: sum of 2 quarters · filed 2023-02-03 | $22.38M 10-Q · filed 2023-02-03 | $27.87M derived: sum of 4 quarters · filed 2023-02-03 |
| 2021-09-30 | $8.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-04 | $12.22M 10-Q · filed 2022-11-04 | $17.71M derived: sum of 3 quarters · filed 2022-11-04 | $23.70M derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $3.86M 10-Q · filed 2022-08-05 | $9.35M derived: sum of 2 quarters · filed 2022-08-05 | $15.34M derived: sum of 3 quarters · filed 2022-08-05 | $18.70M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $5.49M derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-08 | $11.48M derived: sum of 2 quarters · filed 2022-06-08 | $14.84M derived: sum of 3 quarters · filed 2022-06-08 | $18.82M 10-K · filed 2022-06-08 |
| 2020-12-31 | $5.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-02-04 | $9.35M derived: sum of 2 quarters · filed 2022-02-04 | $13.33M 10-Q · filed 2022-02-04 | $15.17M derived: sum of 4 quarters · filed 2022-02-04 |
| 2020-09-30 | $3.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-11-05 | $7.34M 10-Q · filed 2021-11-05 | $9.18M derived: sum of 3 quarters · filed 2021-11-05 | $10.60M derived: sum of 4 quarters · filed 2021-11-05 |
| 2020-06-30 | $3.98M 10-Q · filed 2021-08-09 | $5.82M derived: sum of 2 quarters · filed 2021-08-09 | $7.24M derived: sum of 3 quarters · filed 2021-08-09 | $10.37M derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | $1.84M derived: 10-K 12 month − 10-Q 9 month · filed 2021-06-01 | $3.25M derived: sum of 2 quarters · filed 2021-06-01 | $6.39M derived: sum of 3 quarters · filed 2021-06-01 | $6.96M 10-K · filed 2021-06-01 |
| 2019-12-31 | $1.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-02-16 | $4.55M derived: sum of 2 quarters · filed 2021-02-16 | $5.12M 10-Q · filed 2021-02-16 | $5.36M derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-09-30 | $3.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-11-12 | $3.71M 10-Q · filed 2020-11-12 | $3.94M derived: sum of 3 quarters · filed 2020-11-12 | |
| 2019-06-30 | $572.00K 10-Q · filed 2020-08-12 | $806.00K derived: sum of 2 quarters · filed 2020-08-12 | ||
| 2019-03-31 | $234.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-29 | $1.31M 10-K · filed 2020-06-29 | ||
| 2018-12-31 | $1.07M 10-Q · filed 2020-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |